NAFLD

December 1, 2021
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
Summary Background & aims Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, yet largely underappreciated liver condition which is closely associated with obesity and metabolic disease. Despite affecting an estimated 1 in 4 adults globally, NAFLD is largely absent on national and global health agendas. Methods We collected data from 102 countries, accounting for […]

Read More
June 13, 2020
Editorial: increasing burden of nonalcoholic fatty liver disease-a call to action. Authors’ reply
Summary No abstract available. Countries: Singapore, South Korea

Read More
June 9, 2020
Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study
Summary Background Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) account for a growing proportion of liver disease cases, and there is a need to better understand future disease burden. We used a modelling framework to forecast the burden of disease of NAFLD and NASH for Canada. Methods We used a Markov model to […]

Read More
March 4, 2020
Modelling NAFLD disease burden in four Asian regions-2019-2030
Summary Background Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) account for an increasing proportion of liver disease in the Asia-Pacific region. Many areas in the region are experiencing epidemics of metabolic syndrome among rapidly ageing populations. Aims To estimate using modelling the growth in NAFLD populations, including cases with significant fibrosis that are […]

Read More
February 26, 2020
Nonalcoholic fatty liver disease burden: Australia, 2019-2030
Summary Background and Aim Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) account for a large and growing proportion of liver disease burden globally. The burden of NAFLD/NASH manifests in increasing levels of advanced liver disease and primary liver cancer in Australia. A Markov model was used to forecast NAFLD burden in Australia through […]

Read More
December 17, 2019
Nonalcoholic fatty liver disease burden – Switzerland 2018-2030
Summary As a result of epidemic levels of obesity and diabetes mellitus, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) will contribute to increases in the liver-related disease burden in Switzerland. A Markov model was built to quantify fibrosis progression among the NAFLD and NASH populations, and predict disease burden up to 2030. Long-term […]

Read More
June 8, 2018
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Summary Background & Aims Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease […]

Read More
June 1, 2018
Nonalcoholic fatty liver disease burden – Saudi Arabia and United Arab Emirates, 2017–2030
Summary Background/Aim Due to epidemic levels of obesity and type 2 diabetes mellitus (DM), nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) will be driving factors in liver diseaseburden in the coming years in Saudi Arabia and United Arab Emirates (UAE). Materials and Methods Models were used to estimate NAFLD and NASH disease […]

Read More
December 1, 2017
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Summary Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) are highly prevalent in the United States, where they are a growing cause of cirrhosis and hepatocellular carcinoma (HCC) and increasingly an indicator for liver transplantation. A Markov model was used to forecast NAFLD disease progression. Incidence of NAFLD was based on historical and […]

Read More